Table 1 Results of the immunoistochemistry test with HercepTest or Ventana 4B5 and silver in situ hybridization (SISH)
From: Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
HercepTest 3+ | HercepTest 2+ | HercepTest 1+ | HercepTest 0 | Total | SISH amplified | |
|---|---|---|---|---|---|---|
(A) Archival cohort: KRAS exon 2 (codon 12/13) mutated samples | ||||||
VENTANA 3+ | 0 | 0 | 0 | 0 | 0 | — |
VENTANA 2+ | 0 | 1 | 4 | 1 | 6 | — |
VENTANA 1+ | 0 | 0 | 9 | 14 | 23 | — |
VENTANA 0 | 0 | 0 | 2 | 13 | 15 | — |
Total | 0 | 1 | 15 | 28 | 44 | — |
SISH amplified | — | — | — | — | — | 0/44 |
(B) Archival cohort: KRAS exon 2 (codon 12/13) WT samples | ||||||
VENTANA 3+ | 14 | 1 | 0 | 1 | 16 | 94.1% |
VENTANA 2+ | 0 | 1 | 10 | 12 | 23 (1) | 5.9% |
VENTANA 1+ | 0 | 1 | 43 | 51 | 95 | — |
VENTANA 0 | 0 | 0 | 8 | 162 | 170 | — |
Total | 14 | 3 (2) | 61 | 226 (1) | 304 (17) | 100.0% |
Percentage of amplified | 82.4% | 11.8% | — | 5.9% | 100.0% | 17/304 (5.6%) |
